Mayne Pharma (ASX: MYX) has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million.
Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories.
The US-based firm is backed by healthcare-focused private equity firm Avista Healthcare Partners and funds controlled by private markets investment management firm Hamilton Lane.
Mayne Pharma chief executive officer Shawn Patrick O’Brien said this was a pivotal moment in Mayne’s journey to improve patient access to life-enhancing medications.
“Attracting an offer from a strategic buyer who is active in the US dermatology and women’s health markets, such as Cosette, reflects the excellent work our teams have been doing to strengthen our company over the last year and more,” chair Frank Condella added.
Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by more than 350 team members across all operations.
The Mayne Pharma board has unanimously recommended that shareholders vote in favour of the scheme, which is fully funded and subject to limited customary conditions.
“The board believes that the proposed transaction is in line with its priority to deliver value to our shareholders and also provides significant benefits for our broader stakeholders,” Mr Condella said.
The $7.40 offer price represents a premium of 37% to Mayne Pharma’s closing share price as at 20 February 2025 and a 42% premium to the 30-day volume weighted average price.
Cosette Pharma chief executive officer Apurva Saraf said the acquisition marked a transformational step for the company, adding patented, high-growth products to solidify its leadership in women’s health in the US while expanding its reach globally.
“By combining Cosette’s strong portfolio with Mayne Pharma’s proven commercial expertise, the combined company will be well-positioned to further invest in innovation, portfolio expansion and better serve our patients,” he said.
“We look forward to a timely closing and welcoming Mayne Pharma to the Cosette family.”
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。